Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2014-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1805
- Registration Number
- NCT01996332
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 401
- Registration Number
- NCT01995201
A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.
- Conditions
- Atherosclerosis
- Interventions
- Other: NS followed by LS diet conditionOther: LS followed by NS diet conditionDrug: Placebo
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2016-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT01995383
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 657
- Registration Number
- NCT01991340
A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers
- Conditions
- Healthy Volunteer
- Interventions
- Drug: placebo
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2015-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01991990
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 33
- Registration Number
- NCT01990261
An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)
- Conditions
- Malignant Melanoma
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 339
- Registration Number
- NCT01990248
- Locations
- 🇦🇹
LKH Feldkirch; Onkologie, Feldkirch, Austria
🇦🇹Ordensklinikum Linz Elisabethinen ; Dermatologie, Linz, Austria
🇦🇹Krankenhaus Hietzing Wien, Wien, Austria
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01988896
- Locations
- 🇺🇸
Massachusets General Hospital Clinical Trial Network and Institute, Boston, Massachusetts, United States
🇺🇸Compass Oncology, Portland, Oregon, United States
🇺🇸Texas Oncology, P.A., Arlington, Texas, United States
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.
- Conditions
- Rheumatoid Arthritis
- Interventions
- Biological: tocilizumab
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT01988012
MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for Lymphoma
- First Posted Date
- 2013-11-19
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT01987505
- Locations
- 🇪🇸
Hospital General de Castellon; Servicio de Hematologia, Castellon, Spain
🇪🇸Hospital Universitario Virgen de las Nieves; Servicio de Hematologia, Granada, Spain
🇪🇸Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain